Jeddah,
King Faisal Specialist Hospital and Research Centre (KFSHRC) in Jeddah has achieved a significant breakthrough in treating severe Xanthoma by implementing an advanced plasma exchange protocol, a KFSHRC press release said. This milestone highlights KFSHRC’s role as a pioneer in healthcare innovation and patient care, especially in addressing complex medical cases.
Xanthoma, marked by the accumulation of triglyceride-filled deposits under the skin, poses dermatological and systemic health challenges. KFSHRC has focused on developing innovative treatment protocols to address the recurring nature of the condition and the difficulty in finding lasting solutions.
According to the release, a notable case involved a 58-year-old patient who, after battling Xanthoma for 26 years and seeking treatments worldwide, found hope in KFSHRC’s treatment strategy.
Central to KFSHRC’s intervention was implementing a modified plasma exchange technique tailored to address the unique complexities of such severe Xanthoma. This technique particularly tackled the patient’s extreme triglyceride levels and halted the disease’s progression. The integration of advanced apheresis technology and state-of-the-art imaging and diagnostic tools enabled the team to understand the disease and its impact thoroughly, laying the foundation for an effective treatment plan.
This effort was the culmination of a multidisciplinary collaboration among nutritionists, endocrinologists, and immunohematologists to formulate a holistic treatment strategy. This therapeutic strategy is now published in JCEM, a world-leading peer-reviewed journal for endocrine clinical research and clinical practice—the treatment protocol combined dual action to mitigate the visible symptoms and address the root causes of Xanthoma.
This technique, characterized by its precision and effectiveness, marks a significant advancement in treatment modalities. It introduces innovative ways to tackle previously deemed untreatable conditions, thereby setting new standards in patient-centered care.
Additionally, the release underscored that this comprehensive approach, involving advanced expertise and cutting-edge skills in removing harmful biological substances via extracorporeal circulation, demonstrates the hospital’s adaptability, proficiency, and commitment to pushing the boundaries of medical care.
Chairman of the Department of Pathology and Laboratory Medicine at Jeddah KFSHRC Prof. Ashraf Dada, who led the medical care team, said, “In addressing the patient’s challenging case of xanthoma, where multiple treatment modalities previously failed, we combined our clinical insights with an innovative application of modified plasma exchange, emphasizing our commitment to personalized healthcare.” He emphasized that this method, though less common, was chosen for its potential to specifically target the patient’s condition.
KFSHRC’s achievement in treating Xanthoma not only establishes new benchmarks in medical care but also demonstrates the potential of innovative treatment protocols to significantly improve patients’ quality of life and contribute to scientific advancement.
“As KFSHRC continues to pioneer medical breakthroughs, its stature as a global healthcare leader becomes increasingly evident. The institution’s proactive engagement in medical research and innovation, alongside its dedication to sharing insights and fostering international collaborations, introduces new paradigms in the comprehension and treatment of complex diseases,” the release read.
Further advancing these efforts, KFSHRC’s breakthrough not only provides hope for those with similar conditions but also places the institution at the forefront of medical innovation, highlighting its commitment to research, clinical excellence, and patient experience.
–SPA
